Leidos Holdings Inc

LDOS remains in a Stage 4 decline with price below the 9- and 20-day EMAs and hovering near the 50-day SMA support. Medium-term directional bias is bearish under structural repair, and short-term conditions are unfavorable for further selling given oversold RSI and exhaustion signals. Execution is deferred until rallies into the 9/20-EMA resistance zone offer cleaner trim opportunities. Long-term bias remains bearish as price stays below the declining 200-day SMA, anchoring downside risk.

• ↑Q2 revenue rose 7% YoY to $4.6B with 13.8% adj. EBITDA margin
• ↑Defense segment book-to-bill at 2.2 signals strong customer demand
• ↓Health segment contraction risk from removal of VA incentive payments